Spondyloarthritis & psoriatic arthritis
Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network
Authors' conclusion
All-cause mortality remains elevated in axSpA and PsA, particularly in axSpA. Male sex predicts poorer survival, whereas TNF inhibitor therapy is associated with improved outcomes.
Study context
- Population
- Adults with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA), anonymised EHRs from >100 healthcare organisations worldwide, 2010–2020propensity score matched
- Participants
- 32,368 / 52,402 / 9,742,949
- Exposure
- axSpA and PsA vs each other and vs matched general population controls
- axSpAn = 32,368
- PsAn = 52,402
- General populationn = 9,742,949reference
- Outcome
- All-cause mortality
Methodological detailspropensity-score matched, multinational, TriNetX Global Collaborative Network
- Propensity-score matched
- Multinational
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
Hazard ratio (95% CI)
axSpAvs General population
1.71(1.61–1.81)
PsAvs General population
1.26(1.20–1.32)
axSpAvs PsAMortality was 42% greater in axSpA than PsA
1.42(1.34–1.51)
Observational data: associations, not effects.
Further findings
All-cause mortality by sex (male sex)
- Male sex, axSpA: HR
- 1.65
- Male sex, PsA: HR
- 1.26
- Male sex was associated with increased mortality
All-cause mortality with b/tsDMARD treatment (particularly TNFi) vs untreated
- Mortality reduction in axSpA
- 47%
- Mortality reduction in PsA
- 38%
Original publication
Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network. RMD Open. Published 13 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →